Abstract:Abstract Triple Negative Breast Cancer (TNBC) is an aggressive subtype of breast cancer with high metastatic potential and increased morbidity and mortality. Although expression of and signaling by the epidermal growth factor receptor (EGFR) is commonly seen in TNBC, anti-EGFR antibodies such as Cetuximab have had limited therapeutic efficacy, used alone or in combination with chemotherapy. Primary TNBC tumor growth and metastases require supporting vasculature, which develops through a combination of endothelial angiogenesis and vasculogenic mimicry (VM). VM is frequently seen in TNBC and is associated with aggressive metastatic behavior. We previously developed αEGFR-E-P125A, an antibody-endostatin fusion protein, linking an anti-EGFR antibody to a mutated version of the anti-angiogenic protein endostatin (E-P125A). αEGFR-E-P125A delivers a dimeric E-P125A payload which inhibits TNBC angiogenesis and VM in vitro and in vivo, and markedly decreases metastasis in multiple TNBC xenograft models. To study changes in the transcriptome following induction of VM and inhibition of VM with αEGFR-E-P125A, RNA-seq was conducted on MDA-MB-231-4175 TNBC cells grown in a 2D monolayer and compared to TNBC cells undergoing VM when plated in matrigel. A second comparison was made between TNBC cells undergoing VM and TNBC cells in which VM was inhibited by treatment with αEGFR-E-P125A. Differential gene expression analysis and gene set enrichment analysis (GSEA), were used to define pathways which were inversely regulated during the induction of VM on matrigel and inhibition of VM with αEGFR-E-P125A. Gene set enrichment analysis demonstrated that αEGFR-E-P125A treatment significantly downregulated genes in the JAK-STAT and angiogenesis signaling pathways. Phospho-array analysis demonstrated decreased EGFR phosphorylation at Y1069 in addition to decreased phosphorylation of FAK Y397 and STAT3 Y705 sites downstream of α5β1 integrin. Since inhibition of EGFR signaling alone did not inhibit VM, and endostatin is a known ligand of α5β1 integrin, we focused on effects of αEGFR-E-P125A on inhibition of α5β1 integrin/FAK signaling pathway. Independent siRNA knockdowns of α5 integrin and FAK in MDA-MB-231-4175 cells confirmed that downregulation of α5 integrin/FAK signaling inhibited VM in vitro. αEGFR-E-P125A additionally prevented EGF-induced EGFR phosphorylation and fibronectin-induced FAK phosphorylation by α5β1 integrin. Treatment of TNBC cells with αEGFR-E-P125A reduced total α5 integrin protein levels and decreased co-localization of EGFR and α5β1 integrin receptors. These results indicate that αEGFR-E-P125A suppressed both EGFR and α5β1 integrin signaling. Simultaneous inhibition of EGFR and α5β1integrin signaling by αEGFR-E-P125A fusion is a promising approach to inhibition of TNBC growth and metastases. Citation Format: Ankita Sankar, Hava Gil Henn, Hyun Mi Cho, Dania Nassar, Sundaram Ramakrishnan, Yu Zhang, Christian Elledge, Seung Uon Shin, Joseph Rosenblatt. Mechanism of anti-EGFR antibody endostatin fusion protein action on inhibition of vasculogenic mimicry and tumor cell motility in triple negative breast cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 6319.

The role of EGFR MAbs C225 in breast cancer stem cells

Effect of Fibroblasts on Breast Cancer Cell Mammosphere Formation and Regulation of Stem Cell-Related Gene Expression.

Cd44(Hi)Cd24(Lo) Mammosphere-Forming Cells From Primary Breast Cancer Display Resistance To Multiple Chemotherapeutic Drugs

Enrichment of Breast Cancer Stem Cells and Its Association with Clinicopathological Characteristics

Abstract 1281: Endothelial Cells Promote the Cancer Stem Cell Phenotype of Human Colorectal Cancer Cells

EGFR Inhibitor C225 Increases the Radio-Sensitivity of Human Breast Cancer Cells

Epidermal growth factor receptor blocker C225 increases chemosensitivity and radiosensitivity of Docetaxel resistant human lung adenocarcinoma cell line SPC-A-1/docetaxel

A Preliminary Study of the Role of Extracellular -5′- Nucleotidase in Breast Cancer Stem Cells and Epithelial-Mesenchymal Transition

Involvement Of Egfr In The Promotion Of Malignant Properties In Multidrug Resistant Breast Cancer Cells

EGFR inhibition blocks cancer stem cell clustering and lung metastasis of triple negative breast cancer

Combination Treatment with EGFR Inhibitor and Doxorubicin Synergistically Inhibits Proliferation of MCF-7 Cells and MDA-MB-231 Triple-Negative Breast Cancer Cells In Vitro

Targeting Notch and EGFR signaling in human mucoepidermoid carcinoma

Epidermal growth factor receptor inhibition potentiates chemotherapeutics-mediated sensitization of metastatic breast cancer stem cells

EGFR/HER2 inhibitors effectively reduce the malignant potential of MDR breast cancer evoked by P-gp substrates in vitro and in vivo.

Abstract 6319: Mechanism of anti-EGFR antibody endostatin fusion protein action on inhibition of vasculogenic mimicry and tumor cell motility in triple negative breast cancer

Enhancement of Cetuximab on Radiosensitivity of Colorectal Cancer Cells Exposed to 125I Seeds

Radiosensitivity of Prostate Cancer Cells is Enhanced by EGFR Inhibitor C225

Modeling breast cancer-associated c-Src and EGFR overexpression in human MECs: c-Src and EGFR cooperatively promote aberrant three-dimensional acinar structure and invasive behavior

Role of RAd-p53、E1B - -OLV and Paclitaxel on Breast Cancer Stem Cells

TFEB and TFE3 Depletion Increases Cancer Stem Cell Characteristics and EMT in Triple‐Negative Breast Cancer